SUN-275 DOSE EQUIVALENCY AND EFFICACY OF BIOSIMILAR ERYTHROPOIETIN STIMULATING AGENTS: DATA FROM REAL CLINICAL PRACTICE

Abduzhappar Gaipov, Alpamys Issanov, Zhanar Mursalova, Nazia Tulegenova, Zoya Kakim, Mukhit Baizakov, Mohamad Aljofan, Saltanat Tuganbekovа

2020

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.1016/j.ekir.2020.02.811
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Renal anemia is a common complication of end stage renal disease (ESRD) that require continuous replacement therapy with recombinant human erythropoietin stimulating agents (rESA) in most patients. Biosimilar erythropoietin stimulating agents (bESA) are available in Kazakhstan and that most of the dialysis centers switched their patients into the more cost effective bESA. However, important properties of bESA such as dose equivalency to rESA and the ability to maintain hemoglobin (HB) target levels were unknown.